BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2026)
BridgeBio Pharma (BBIO) posted Change in Receivables of $65.8 million for Q1 2026, up 186.93% sequentially from $22.9 million in Q4 2025, and down 40.49% YoY from $110.5 million in Q1 2025.
BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2026) Analysis & Trends
BridgeBio Pharma has reported Change in Receivables for 3 years, with the latest figure at $65.8 million in Q1 2026.
- Quarterly Change in Receivables fell 40.49% year-over-year to $65.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90.0 million (up 174.82% YoY) and the FY2025 annual result came in at $134.7 million, up 4434.57% from the prior year.
- Change in Receivables advanced to $65.8 million in Q1 2026 per BBIO's latest filing, from $22.9 million in the prior quarter.
- Over five years, Change in Receivables peaked at $233.7 million in Q1 2024 and troughed at -$234.8 million in Q2 2024.
- A 3-year average of $22.6 million and a median of $22.9 million in 2025 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 21885.71% in 2025, down 52.71% in 2025.
- Over 3 years, Change in Receivables stood at $4.2 million in 2024, then soared by 440.2% to $22.9 million in 2025, then surged by 186.93% to $65.8 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $65.8 million, $22.9 million, and $39.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 49.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.26 Mn |
| Jun 30, 2026 | 49.26 Mn |
| Mar 31, 2026 | 65.78 Mn |
| Mar 31, 2026 | 65.78 Mn |
| Dec 31, 2025 | 22.93 Mn |
| Dec 31, 2025 | 22.93 Mn |
| Sep 30, 2025 | 39.65 Mn |
| Sep 30, 2025 | 39.65 Mn |
| Jun 30, 2025 | -38.40 Mn |
| Jun 30, 2025 | -38.40 Mn |
| Mar 31, 2025 | 110.54 Mn |
| Mar 31, 2025 | 110.54 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | -182,000.00 |
| Sep 30, 2024 | -182,000.00 |
| Jun 30, 2024 | -234.83 Mn |
| Jun 30, 2024 | -234.83 Mn |
| Mar 31, 2024 | 233.74 Mn |
| Mar 31, 2024 | 233.74 Mn |